239 related articles for article (PubMed ID: 35280743)
1. NCAPG as a Novel Prognostic Biomarker in Glioma.
Jiang X; Shi Y; Chen X; Xu H; Liu B; Zhou F; Huang X; Cho WC; Li L; Pu J
Front Oncol; 2022; 12():831438. PubMed ID: 35280743
[TBL] [Abstract][Full Text] [Related]
2. CCDC103 as a Prognostic Biomarker Correlated with Tumor Progression and Immune Infiltration in Glioma.
Xu Z; Xu H; Chen X; Huang X; Tian J; Zhao J; Liu B; Shi F; Wu J; Pu J
Onco Targets Ther; 2023; 16():819-837. PubMed ID: 37873495
[TBL] [Abstract][Full Text] [Related]
3. MRPS23 is a novel prognostic biomarker and promotes glioma progression.
Wang Q; Chen G; Liu L; Peng X; Yang X; Yang L; Li C
Aging (Albany NY); 2024 Jan; 16(3):2457-2474. PubMed ID: 38301044
[TBL] [Abstract][Full Text] [Related]
4. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
[TBL] [Abstract][Full Text] [Related]
5. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
6. NCAPG Promotes Tumor Progression and Modulates Immune Cell Infiltration in Glioma.
Zheng G; Han T; Hu X; Yang Z; Wang J; Wen Z; Li H; Wang H
Front Oncol; 2022; 12():770628. PubMed ID: 35372056
[TBL] [Abstract][Full Text] [Related]
7.
Ge X; Xu M; Cheng T; Hu N; Sun P; Lu B; Wang Z; Li J
Front Immunol; 2022; 13():974346. PubMed ID: 36275718
[TBL] [Abstract][Full Text] [Related]
8. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation-regulated YTHDF2 correlates with cell migration and immune cell infiltration in glioma.
Jiang X; Chen X; Huang X; Wang C; Wang C; Pan C; Cho WC; Nie Z; Pu J; Wang W
Aging (Albany NY); 2022 Jun; 14(19):7774-7793. PubMed ID: 35661004
[TBL] [Abstract][Full Text] [Related]
10. Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma.
Chai RC; Wang N; Chang YZ; Zhang KN; Li JJ; Niu JJ; Wu F; Liu YQ; Wang YZ
Cancer Cell Int; 2019; 19():155. PubMed ID: 31171919
[TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
[TBL] [Abstract][Full Text] [Related]
12.
Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X
J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118
[TBL] [Abstract][Full Text] [Related]
13. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
Front Neurol; 2022; 13():977180. PubMed ID: 36353126
[TBL] [Abstract][Full Text] [Related]
14. The N6-Methylandenosine-Related Gene
Jiang X; Shi Y; Chen X; Xu H; Huang X; Li L; Pu J
Front Mol Biosci; 2022; 9():773662. PubMed ID: 35309512
[TBL] [Abstract][Full Text] [Related]
15. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
16. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
Front Oncol; 2021; 11():611038. PubMed ID: 33937022
[TBL] [Abstract][Full Text] [Related]
17. Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma.
Lv L; Zhang Y; Zhao Y; Wei Q; Zhao Y; Yi Q
Front Cell Neurosci; 2021; 15():704344. PubMed ID: 34335194
[No Abstract] [Full Text] [Related]
18. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
[TBL] [Abstract][Full Text] [Related]
19. CNPY4 is a potential promising prognostic-related biomarker and correlated with immune infiltrates in gliomas.
Li JW; Huang QR; Mo LG
Medicine (Baltimore); 2022 Aug; 101(33):e30044. PubMed ID: 35984129
[TBL] [Abstract][Full Text] [Related]
20. LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages.
Hu WM; Yang YZ; Zhang TZ; Qin CF; Li XN
Front Med (Lausanne); 2020; 7():182. PubMed ID: 32528967
[No Abstract] [Full Text] [Related]
[Next] [New Search]